Bio-Techne (TECH) Stock: Buy, Sell, or Hold?
TECH - Bio-Techne Corp.
$72.12
0.04 (0.06%)
â˛
5d:
-0.46%
30d:
-0.15%
90d:
+33.51%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When TECH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TECH is fairly priced but lacks strong directional signals. At 13.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TECH is fairly priced but lacks strong directional signals. At 13.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$30.06
Based on -6.4% avg growth
INTRINSIC VALUE TODAY
$18.67
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TECH is currently trading at $72.12, which is considered slightly low relative to its 30-day fair value range of $72.12 to $72.40. From a valuation perspective, the stock is trading at a premium (Forward PE: 42.4) compared to its historical average (29.3). At these levels, the market is pricing in 13.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TECH is in a strong uptrend. The price is currently testing key support at $72.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TECH scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TECH is in a strong uptrend. The price is currently testing key support at $72.08. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TECH scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$72.12 -
$72.40
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($70.73)
- NEUTRAL: PE elevated vs history but 13.1% growth expectation is conservative given 129% recent growth
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$72.12 -
$72.40
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$72.08
Resistance Level
$72.58
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
42.42
Wall Street Target
$70.73
(-1.9%)
Revenue Growth (YoY)
1.3%
Earnings Growth (YoY)
128.6%
Profit Margin
15.0%
Valuation Premium vs History
+13.1% premium
PE vs Historical
42.4 vs 29.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+13.1%
(market-implied from PE analysis)
1-Year Target
$81.57
(+13%)
2-Year Target
$92.25
(+28%)
3-Year Target
$104.34
(+45%)
3-Yr Target (if PE normalizes)
(PE: 42â29)
PE COMPRESSION
$72.06
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 42.4, Growth: -16.8%)
$52.58
(+-27%)
Base:
(SPY PE: 20.2, Growth: -16.8%)
$25.00
(-65%)
Bear:
(PE: 17.1, Growth: -16.8%)
$21.25
(-71%)
đ
Valuation based on Current Earnings
Forward PE: 34.48 | Forward EPS (Implied): $2.09
Bull Case
$87.08
(+21%)
Analyst growth 15.0%, PE expands to 36.2
Base Case
$72.12
(0%)
Market implied 0.0%, PE stable at 34.5
Bear Case
$55.17
(-24%)
Severe decline -15.0%, PE contracts to 31.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 3:10 PM ET
Data refreshes hourly during market hours. Next update: 4:10 PM
Data refreshes hourly during market hours. Next update: 4:10 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TECH showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
NEUTRAL
Recent Transactions
Ro Khanna
BUY
2026-03-30
April McClain Delaney
SELL
2026-03-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
